A new IMS report
released Monday offers suggestions for helping alleviate drug shortages, including an Early Warning System.
highlights that the underlying causes of the problem remain complex and require more systematic research across the total supply chain. This drug shortage problem is highly concentrated and almost entirely affects generic injectable drugs, which means that the affected patients are mostly acute care patients being treated by providers in hospitals and out-patient facilities. As we've said before, notifying FDA
of anticipated occurrences of a drug shortage early in the process helps the FDA, health care providers and manufacturers to identify and provide appropriate treatment alternatives more efficiently, and the IMS report seems to underscore this point.
Manufacturers warning the FDA of anticipated events that might lead to shortages have prevented at least 99 drug shortages in 2011 - this early notification by manufacturers is helping to save lives, and we're going to continue to find ways to improve upon communication and collaboration with the FDA and others in the supply chain.
I encourage you to check out the report. It provides an overview of where the problem is concentrated within the supply chain and also contains a great deal of information about drug volume and sale of products.